- The NanoAbs may provide improve upon existing treatments such as Paxlovid, which has several contraindications
- The company’s pipeline of alpaca-derived NanoAb therapies aims to address diseases with large underserved medical needs, including COVID-19, asthma, psoriasis, and more
- The global COVID-19 therapy market was valued at $16.8 billion in 2021 and is expected to grow at a CAGR of 20%, resulting in a value of $35.42 billion by 2025
A study recently published in JAMA Network found that nearly 15% of COVID-19 patients admitted to 36 Paris University hospitals had contraindications (excluding factors) to Paxlovid, the leading COVID-19 treatment. While Paxlovid can reduce hospitalization and death among high-risk COVID-19 patients, there are situations where it is not recommended due to ritonavir’s ability to increase concentrations of drugs that strongly depend on hepatic cytochrome P-450 3A metabolism. The study further supports the argument and necessity for radically improved COVID-19 treatments (https://ibn.fm/h26qS).
BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotechnology company focused on the development, manufacturing, and commercialization of innovative immunotherapeutic products primarily treating infectious and autoimmune diseases, announced statistically significant (p<0.001) efficacy results in a preclinical in-vivo proof-of-concept study of its innovative inhaled nanosized antibody (NanoAb) COVID-19 therapy (https://ibn.fm/j25pD).
BiondVax is developing a pipeline of alpaca-derived NanoAb therapies to address diseases with large underserved medical needs, including COVID-19, asthma, psoriasis, psoriatic arthritis, and macular degeneration. Compared with current monoclonal antibodies (“mAbs”) treatments, BiondVax’s NanoAbs exhibit strong potential for superior patient convenience, safety, and clinical outcomes, at a lower cost.
BiondVax’s study was designed using an industry-standard animal model for COVID-19 therapeutics and vaccines and compared weight loss in two groups of hamsters after infection with SARS-COV-2. The experimental group was treated with the company’s anti-COVID-19 NanoAb, administered via inhalation, starting one day after infection. The control group was treated in the same manner but with saline as a placebo. These studies were conducted by The Fraunhofer Institute for Toxicology and Experimental Medicine (“ITEM”) and The University of Veterinary Medicine Hannover (“TiHo”), Germany, two world-renowned institutions.
The study concluded that compared to pre-infection weight, the control group’s weight declined on average at 12.01%. In contrast, on average the weight of the experimental group using BiondVax’s NanoAb therapy declined only 3.80%. The successful result of the study was further supported by eight other tracked parameters, including heart rate and social behaviors, indicating that the group treated with NanoAbs experienced a milder, shorter illness.
According to Research and Markets, the global COVID-19 therapy market was valued at $16.8 billion in 2021 and is expected to grow at a CAGR of 20%, resulting in a value of $35.42 billion by 2025. A key factor driving the therapy market’s growth is the fact that social restrictions in place during the pandemic have generally eased, and preventative vaccine and booster uptake is waning, with an expected consequence of more COVID infections requiring treatment. (https://ibn.fm/lx8iz).
“We are excited that the study results confirm the inhalation concept of our exclusively licensed NanoAb as a therapy for COVID-19 illness,” said BiondVax’s Chief Science Officer (“CSO”), Dr. Tamar Ben-Yedidia Ph.D. “Following these promising results, we intend to continue the study early next year by testing additional dose levels of the inhaled NanoAb therapy and as a prophylactic (preventive) treatment. Results of the trial will inform design of the first-in-human clinical trial of the inhaled NanoAb COVID-19 therapy, which is planned for late 2023.”
For more information, visit the company’s website at www.BiondVax.com.
NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://ibn.fm/BVXV
About MissionIR
MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
For more information, visit www.MissionIR.com
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
